Latest Breaking News On - Randi isaacs - Page 2 : comparemela.com

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

24.02.2023 - WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in Patients with Advanced or Metastatic Solid Tumors . Seite 1

Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

06.06.2022 - CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to .

Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights

24.03.2022 - -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -Reported positive preclinical data at SITC demonstrating the potential to drive targeted .

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Hickory Lane Hedge Fund Founder Cleared of Assault Charges